

RICHARD TREAGUS TO JOIN ACRUX BOARD

Acrux (ASX: ACR) today announced that Chief Executive Officer Dr Richard Treagus will join the Acrux Board of Directors. Richard was appointed CEO in May 2006, bringing a track record of building shareholder value at Sigma in Australia and Aspen Pharmacare in South Africa.

Welcoming Richard onto the Board, Acrux Chairman Ross Dobinson commented; "In the ten months that Richard has been CEO, Acrux's share price has increased by 76%. Richard has made excellent progress executing his mandate and accelerating the commercialisation of our unique drug delivery technology."

Contact

Ross Dobinson, Chairman: +61 418 347 494

About Acrux - www.acrux.com.au

- Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.
- Fast-drying, invisible sprays or liquids provide a delivery platform with low or no skin irritation, superior cosmetic acceptability and simple, accurate and flexible dosing. The technology platform is covered by broad and well-differentiated, issued patents.
- Acrux's products in clinical development include:
 - Estradiol MDTS[®] (EvaMist[™] in the USA) to treat menopause symptoms
 - Testosterone MDTS[®] to treat decreased libido in women
 - Testosterone MD-Lotion[®] to treat testosterone deficiency in men
 - Nestorone[®] MDTS[®] contraceptive spray for women
 - Fentanyl MDTS[®] to treat chronic pain
- Acrux has licensed worldwide rights to its technology for selected contraceptives and for an undisclosed proprietary drug to ORGANON, USA rights for Estradiol MDTS[®] and Testosterone MDTS[®] to VIVUS and AUS/NZ distribution rights for Testosterone MDTS[®] and Fentanyl MDTS[®] to CSL Limited. Acrux has also licensed its technology to Eli Lilly and Company for veterinary healthcare products.